Skip to Main Content
Table 3.

Univariate analysis for overall and disease-free survival

VariableOverall survival
Disease-free survival
No. patientsHR (95% CI)PNo. patientsHR (95% CI)P
β1 integrin intensity 146 1.43 (1.04–1.97) 0.03* 146 1.48 (0.98–2.21) 0.06* 
    0 32 1  32 1  
    1 72 1.17 (0.51–2.70) 0.71 74 1.23 (0.43–3.50) 0.69 
    2 27 1.65 (0.63–4.33) 0.31 27 0.72 (0.17–3.01) 0.65 
    3 15 2.89 (1.08–7.72) 0.03 15 4.13 (1.31–13.0) 0.02 
ECM fibronectin intensity 108 1.03 (0.65–1.65) 0.87* 105 1.40 (0.72–2.71) 0.32* 
    0 66 1  64 1  
    1 35 0.87 (0.40–1.92) 0.73 34 0.73 (0.37–3.18) 0.88 
    2 6 1.20 (0.28–5.17) 0.80 6 0.80 (0.13–7.97) 0.98 
    3 1 8.53 (1.08–67.1) 0.04 1 13.76 (1.63–115.9) 0.02 
ECM laminin-1 intensity 133 0.95 (0.69–1.31) 0.76* 105 0.94 (0.57–1.57) 0.83* 
    0 89 1  24 1  
    1 10 1.20 (0.42–3.45) 0.73 35 0.62 (0.08–4.80) 0.51 
    2 28 0.61 (0.27–1.41) 0.25 28 0.80 (0.23–2.85) 0.80 
    3 6 2.08 (0.64–6.83) 0.22 18 1.17 (0.15–9.02) 0.87 
Age 145 1.02 (1.003–1.04) 0.03* 145 0.97 (0.94–0.99) 0.02* 
AJCC stage 144 2.43 (1.51–3.91) <0.001* 144 3.05 (1.69–5.51) <0.001* 
    1 57 1  57 1  
    2 72 1.93 (0.93–3.98) 0.07 72 3.37 (1.12–10.11) 0.03 
    3 15 6.17 (2.51–15.15) <0.001 15 9.56 (2.77–33.0) <0.001 
Axillary nodes positive 144 2.26 (1.58–3.23) <0.001 144 1.62 (1.06–2.50) 0.03* 
    0 91 1  91 1  
    1–3 26 1.75 (0.69–4.68) 0.24 26 2.24 (0.88–5.69) 0.24 
    ≥3 27 5.13 (2.55–10.33) <0.001 27 2.58 (1.05–6.32) 0.44 
Tumor size (mm) 148 2.07 (1.48–2.88) <0.001 146 2.44 (1.57–3.78) <0.001 
    0–9 19 1  18 1  
    10–19 62 1.01 (0.36–2.83) 0.99 61 N/A† N/A 
    20–29 34 1.68 (0.53–5.30) 0.38 34 N/A N/A 
    ≥30 33 5.73 (2.03–16.13) <0.001 33 N/A N/A 
Estrogen receptor positive 120 0.60 (0.288–1.27) 0.18 120 0.62 (0.28–1.64) 0.40 
Progesterone receptor positive 140 0.58 (0.31–1.09) 0.09 138 0.62 (0.28–1.34) 0.22 
SBR score 141 1.52 (1.00–2.31) 0.05* 141 2.25 (1.20–4.23) 0.01* 
    1 28 1  27 1  
    2 54 1.66 (0.68–4.25) 0.29 53 4.19 (0.53–33.1) 0.17 
    3 59 2.40 (0.96–6.00) 0.06 61 7.89 (1.04–59) 0.04 
Radiation therapy 143 1.26 (0.675–2.36) 0.46 141 1.13 (0.52–2.43) 0.76 
Chemotherapy 144 1.12 (0.58–2.15) 0.73 142 1.59 (0.74–3.39) 0.22 
Hormone therapy 143 1.27 (0.664–2.43) 0.47 141 0.99 (0.45–2.21) 0.98 
VariableOverall survival
Disease-free survival
No. patientsHR (95% CI)PNo. patientsHR (95% CI)P
β1 integrin intensity 146 1.43 (1.04–1.97) 0.03* 146 1.48 (0.98–2.21) 0.06* 
    0 32 1  32 1  
    1 72 1.17 (0.51–2.70) 0.71 74 1.23 (0.43–3.50) 0.69 
    2 27 1.65 (0.63–4.33) 0.31 27 0.72 (0.17–3.01) 0.65 
    3 15 2.89 (1.08–7.72) 0.03 15 4.13 (1.31–13.0) 0.02 
ECM fibronectin intensity 108 1.03 (0.65–1.65) 0.87* 105 1.40 (0.72–2.71) 0.32* 
    0 66 1  64 1  
    1 35 0.87 (0.40–1.92) 0.73 34 0.73 (0.37–3.18) 0.88 
    2 6 1.20 (0.28–5.17) 0.80 6 0.80 (0.13–7.97) 0.98 
    3 1 8.53 (1.08–67.1) 0.04 1 13.76 (1.63–115.9) 0.02 
ECM laminin-1 intensity 133 0.95 (0.69–1.31) 0.76* 105 0.94 (0.57–1.57) 0.83* 
    0 89 1  24 1  
    1 10 1.20 (0.42–3.45) 0.73 35 0.62 (0.08–4.80) 0.51 
    2 28 0.61 (0.27–1.41) 0.25 28 0.80 (0.23–2.85) 0.80 
    3 6 2.08 (0.64–6.83) 0.22 18 1.17 (0.15–9.02) 0.87 
Age 145 1.02 (1.003–1.04) 0.03* 145 0.97 (0.94–0.99) 0.02* 
AJCC stage 144 2.43 (1.51–3.91) <0.001* 144 3.05 (1.69–5.51) <0.001* 
    1 57 1  57 1  
    2 72 1.93 (0.93–3.98) 0.07 72 3.37 (1.12–10.11) 0.03 
    3 15 6.17 (2.51–15.15) <0.001 15 9.56 (2.77–33.0) <0.001 
Axillary nodes positive 144 2.26 (1.58–3.23) <0.001 144 1.62 (1.06–2.50) 0.03* 
    0 91 1  91 1  
    1–3 26 1.75 (0.69–4.68) 0.24 26 2.24 (0.88–5.69) 0.24 
    ≥3 27 5.13 (2.55–10.33) <0.001 27 2.58 (1.05–6.32) 0.44 
Tumor size (mm) 148 2.07 (1.48–2.88) <0.001 146 2.44 (1.57–3.78) <0.001 
    0–9 19 1  18 1  
    10–19 62 1.01 (0.36–2.83) 0.99 61 N/A† N/A 
    20–29 34 1.68 (0.53–5.30) 0.38 34 N/A N/A 
    ≥30 33 5.73 (2.03–16.13) <0.001 33 N/A N/A 
Estrogen receptor positive 120 0.60 (0.288–1.27) 0.18 120 0.62 (0.28–1.64) 0.40 
Progesterone receptor positive 140 0.58 (0.31–1.09) 0.09 138 0.62 (0.28–1.34) 0.22 
SBR score 141 1.52 (1.00–2.31) 0.05* 141 2.25 (1.20–4.23) 0.01* 
    1 28 1  27 1  
    2 54 1.66 (0.68–4.25) 0.29 53 4.19 (0.53–33.1) 0.17 
    3 59 2.40 (0.96–6.00) 0.06 61 7.89 (1.04–59) 0.04 
Radiation therapy 143 1.26 (0.675–2.36) 0.46 141 1.13 (0.52–2.43) 0.76 
Chemotherapy 144 1.12 (0.58–2.15) 0.73 142 1.59 (0.74–3.39) 0.22 
Hormone therapy 143 1.27 (0.664–2.43) 0.47 141 0.99 (0.45–2.21) 0.98 
*

First HR is for factor considered as a continuous variable.

†

Not available due to 0 recurrence in baseline group.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept